kabutan

Fuji Pharma, Jan-Mar (2Q) Ordinary Profit Decreases by 63%

Thu May 8, 2025 4:30 pm JST Earnings

4554 Fuji Pharma Co.,Ltd. 【J-GAAP】

Earnings Report

Fuji Pharma Co.,Ltd. <4554> [TSE Prime] announced its financial results after the market closed on May 8th (16:30). The consolidated ordinary profit for the cumulative second quarter of the fiscal year ending September 2025 (October 2024 to March 2025) was 2.2 billion yen, a 2.0% increase compared to the same period last year. However, the progress rate toward the full-year plan of 4.68 billion yen was 47.2%, also falling below the five-year average of 63.6%.

Based on the first-half performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated ordinary profit for the April to September period (2H) is expected to grow 8.4% from the same period last year, reaching 2.47 billion yen.

In the most recent three-month period, from January to March (2Q), the consolidated ordinary profit significantly dropped to 0.83 billion yen, a 63.2% decrease compared to the same period last year. The operating profit margin significantly dropped from 14.9% in the same period last year to 9.5%.

Kabutan News

Actual Results

Accumulated Results 2nd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Oct - Mar, 2022 19,225 1,824 2,456 1,772 73.0 54.3 May 11, 2023 J-GAAP
Oct - Mar, 2023 21,388 1,443 2,165 4,257 175.2 48.7 May 9, 2024 J-GAAP
Oct - Mar, 2024 24,095 2,305 2,209 1,287 52.8 47.2 May 8, 2025 J-GAAP
YoY +12.7% +59.7% +2.0% -69.8% -69.8%

First Half Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2024 Guidance 26,150 2,380 2,330 1,650 67.6 20 Nov 12, 2024 J-GAAP
Oct - Mar, 2024 Results 24,095 2,305 2,209 1,287 52.8 20 May 8, 2025 J-GAAP
Revision Rate -7.9% -3.2% -5.2% -22.0% -21.8%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2024 24,750 2,437 2,280 1,889 77.7 22.50 Nov 12, 2024 J-GAAP
Apr - Sep, 2025 Guidance 29,265 2,545 2,471 2,093 85.6 25.50 May 8, 2025 J-GAAP
YoY +18.2% +4.4% +8.4% +10.8% +10.1%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Sep, 2023 40,889 3,858 4,519 3,435 141.4 37 Nov 9, 2023 J-GAAP
Sep, 2024 46,138 3,880 4,445 6,146 252.9 42.50 Nov 12, 2024 J-GAAP
Sep, 2025 Guidance 53,360 4,850 4,680 3,380 138.2 45.50 Nov 12, 2024 J-GAAP
YoY +15.7% +25.0% +5.3% -45.0% -45.3%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jan - Mar, 2024 10,642 1,583 2,261 1,518 62.5 14.9 May 9, 2024 J-GAAP
Apr - Jun, 2024 11,767 772 802 653 26.9 6.6 Aug 8, 2024 J-GAAP
Jul - Sep, 2024 12,983 1,665 1,478 1,236 50.9 12.8 Nov 12, 2024 J-GAAP
Oct - Dec, 2024 13,000 1,252 1,376 991 40.8 9.6 Feb 6, 2025 J-GAAP
Jan - Mar, 2025 11,095 1,053 833 296 12.2 9.5 May 8, 2025 J-GAAP
YoY +4.3% -33.5% -63.2% -80.5% -80.5%

Related Articles